Lilly and Roche team up on new Alzheimer’s diagnostic test
pharmafile | January 28, 2016 | News story | Research and Development | Alzheimer's disease, Diagnostics, Roche, dementia, lilly
Eli Lilly has partnered with Roche Diagnostics to advance its development of a cerebrospinal fluid test for amyloid-beta 1-42, which could be used to diagnose Alzheimer’s disease more effectively.
Along with tau protein tangles in the brain, the presence of amyloid is a key marker of Alzheimer’s disease: the most common form of dementia and a condition with no cure. An estimated 44 million people currently live with dementia worldwide, and it is predicted that about 135 million people will be affected by the condition by 2050.
In developing a more effective test, Lilly hopes to make it easier for clinicians to detect evidence of amyloid- an important step in being able to effectively manage the disease. Currently, healthcare providers can find evidence of amyloid in the living brain through two methods: a cerebrospinal fluid (CSF) test and an amyloid brain positron emission tomography (PET) scan.
Under the agreement, Lilly is responsible for certain milestone payments upon successful completion of key development objectives. Roche will develop, register, and commercialise the new test. Both companies also have potential new treatments for Alzheimer’s disease in Phase III trials.
“We are excited to partner with Roche Diagnostics on this important test,” says Phyllis Ferrell, vice president of Lilly’s Alzheimer’s disease platform. “We share the same commitment to providing people with Alzheimer’s disease the best care possible, which includes detection as well as diagnosis and education.”
Joel Levy
Related Content
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …
Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …
